The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 9th 2024
Remission according to the simplified definition correlated with the 2016 preliminary gout remission definition and GIS score improvements.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
High BMI Can Increase Risk of Gout Associated with Sugar-Sweetened Beverages
September 23rd 2015Sugar-sweetened beverages (SBB) can do more than increase belly fat and send your body on a rollercoaster, it can elevate serum urate levels which increases the risk of gout. Researchers from New Zealand recently looked at how body mass index (BMI) plays a role in the SBB and gout relationship.
OA and RA Treatment: Targeting MGC Cells May Be a Promising Avenue
A study in BMC Musculoskeletal Disorders suggests that multinucleated giant cells (MGC) may contribute to osteoarthritis (OA) and rheumatoid arthritis (RA) in addition to their known association with synovitis severity. The finding adds to other recent research and points to the therapeutic potential of targeting MGCs to improve pain and joint damage in both types of arthritis.
Rheumatoid Arthritis Follow-up Study Suggests Long-term Safety and Efficacy of Combo Therapy
Certolizumab pegol (CZP) + methotrexate (MTX) is safe and effective for patients with rheumatoid arthritis (RA) with disease activity despite methotrexate therapy, according to a five-year follow-up study published in Arthritis Research & Therapy. The finding is an extension of the Rheumatoid Arthritis Prevention of Structural Damage (RAPID 2) randomized, controlled trial. It is important because patients with RA are likely to undergo treatment with anti-tumor necrosis factor (anti-TNF) medications over several years.
Functional ability in early rheumatoid arthritis can be improved with intensive initial therapy with triple disease modifying anti-rheumatic disease (DMARD) drugs, according to results of a study presented at the European League Against Rheumatism Annual Congress in Rome, Italy in June.
Gout Drug May Prevent Kidney Damage Caused by Diabetes
September 16th 2015Gout has been making quite a stir in news recently. Between a new classification system and a study showing that a common food can cause painful flares, this form of arthritis is getting quite a bit of attention. Now comes word that a drug used to treat gout could also be effective for another damaging condition.
Review Suggests Remedies for Clinical Challenges of Lupus Nephritis
A recent review looked at the underlying reasons for the care challenges still facing rheumatologists in treating lupus nephritis (LN). Among those, the review looks at how to better predict individual risk for LN in a patient with systemic lupus erythematosus patient; identify optimal therapy for LN patients, and how to monitor immunologic activity for signs of persistent kidney damage.
Tenosynovitis May Predict Rheumatoid Arthritis
Using an ultrasound to predict tenosynovitis may also predict early rheumatoid arthritis (RA), according to the results of a study presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, Italy earlier this summer.
Do State-Level Opioid Control Programs Decrease Abuse and Diversion?
Like every year, PAINWeek, which kicks off this week in Las Vegas, will include dozens of presentations on abuse and diversion. It is a topic that is always front and center for pain management practitioners, and one for which there are no easy answers.
Major Injury Risk for Rheumatoid Arthritis Patients Using DMARDs
Patients with moderate rheumatoid arthritis (RA) taking disease-modifying anti-rheumatic drugs (DMARDs) have a similar risk of joint fracture that requires surgery as RA patients with high disease activity.
New CDC Program Funds States to Help Prescription Drug Overdose Epidemic
September 8th 2015Every day 46 people in the United States die from a prescription painkiller overdose. As part of its effort to combat this startling epidemic, the Centers for Disease Control and Prevention (CDC) will soon launch a comprehensive prevention program.
Tools That Assess Sarcoidosis Severity Should See More Use Across Specialties
A study in JAMA Dermatology provides evidence that the use of two tests to assess cutaneous sarcoidosis disease severity should be expanded. The research has applications for dermatologists, rheumatologists, and pulmonologists, all of whom have a role in treating sarcoidosis.
Chronic Pain: Lidocaine Metabolite May Help and Open New Avenues of Treatment
Lidocaine metabolite N-ethylglycine (EG) relieves hyperalgesia and allodynia in animal models for chronic pain, suggests a study in Pain. The finding is an indicator that use of Glycine transporter 1 substrates might constitute a new drug target for the modulation of glycinergic inhibition in pain signaling.
Children with Lupus and Diabetes Are Likely to Also Have Depression
Children with systemic lupus erythematosus (SLE)/mixed connective tissue disease (MCTD) often suffer from significant bouts of depression and potentially suicide ideation, a study in the Journal of Pediatrics determined.
Does Proper Placement of a TENS Device Impact Pain Threshold?
A recent study in the Journal of Pain Research found that placing an electrical stimulation device properly doesn't necessarily increase the pain threshold for health patients subjected to transcutaneous electrical nerve stimulation (TENS). The finding is important because TENS is among many nonpharmacological interventions for pain around which clinical opinion on effectiveness is split.